Sam Altman's Latest Startup Merge Labs Enters High-Stakes Brain-Computer Interface Market
In a move that has sent ripples through the tech community, OpenAI CEO Sam Altman has added another startup to his portfolio: Merge Labs, a brain-computer interface (BCI) venture that boasts $252 million in seed funding. The company's ambitious goal is to harness the potential of BCI technology to merge human brains with AI systems, with Altman himself touting this vision as "the merge," which he believes has already begun.
Merge Labs was spun out from Forest Neurotech, a California-based non-profit that Altman co-founded alongside Tyson Aflalo and Sumner Norman. The new venture boasts a diverse team of experts in fields ranging from computational neuroscience to machine learning research, with 19 open positions currently available.
According to the company, Merge aims to develop BCI technologies that interact with the brain at high bandwidth, integrate with advanced AI systems, and are ultimately safe and accessible for anyone to use. Unlike its rival Neuralink, which relies on invasive surgery to implant devices into patients' brains, Merge is focusing on developing non-invasive approaches using molecules, ultrasound, and other modalities.
The company's valuation remains undisclosed, but initial investors include OpenAI, Bain Capital, and video game developer Gabe Newell. While the BCI space has become increasingly crowded in recent months – with Synchron and Neuralink vying for dominance – Merge Labs' emphasis on non-invasive approaches and its integration with advanced AI systems could help it carve out a unique niche.
As Altman himself noted in a 2017 blog post, "the merge" between humans and machines has already begun. With OpenAI backing Merge's efforts and collaborating on projects such as scientific foundation models, the stage is set for this ambitious startup to make its mark on the world of BCI technology.
In a move that has sent ripples through the tech community, OpenAI CEO Sam Altman has added another startup to his portfolio: Merge Labs, a brain-computer interface (BCI) venture that boasts $252 million in seed funding. The company's ambitious goal is to harness the potential of BCI technology to merge human brains with AI systems, with Altman himself touting this vision as "the merge," which he believes has already begun.
Merge Labs was spun out from Forest Neurotech, a California-based non-profit that Altman co-founded alongside Tyson Aflalo and Sumner Norman. The new venture boasts a diverse team of experts in fields ranging from computational neuroscience to machine learning research, with 19 open positions currently available.
According to the company, Merge aims to develop BCI technologies that interact with the brain at high bandwidth, integrate with advanced AI systems, and are ultimately safe and accessible for anyone to use. Unlike its rival Neuralink, which relies on invasive surgery to implant devices into patients' brains, Merge is focusing on developing non-invasive approaches using molecules, ultrasound, and other modalities.
The company's valuation remains undisclosed, but initial investors include OpenAI, Bain Capital, and video game developer Gabe Newell. While the BCI space has become increasingly crowded in recent months – with Synchron and Neuralink vying for dominance – Merge Labs' emphasis on non-invasive approaches and its integration with advanced AI systems could help it carve out a unique niche.
As Altman himself noted in a 2017 blog post, "the merge" between humans and machines has already begun. With OpenAI backing Merge's efforts and collaborating on projects such as scientific foundation models, the stage is set for this ambitious startup to make its mark on the world of BCI technology.